Myspa

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Myspa

Property Description
Active ingredient Hyoscine Butylbromide (Scopolamine Butylbromide)
Form Tablet; Solution for injection
Pharmacological class Anticholinergic; Spasmolytic
General purpose Relief of cramping pain/spasms
Origin Semi-synthetic tropane alkaloid derivative

Myspa: Definition, Type, and Pharmacological Class

Myspa is a pharmaceutical agent containing the active ingredient Hyoscine Butylbromide, which defines the medicine as a potent Antispasmodic agent. Its primary function is providing relief from acute pain associated with the involuntary tightening, or spasms, of smooth muscles in internal organs. The substance is also classified as an Anticholinergic agent, targeting the muscarinic receptors that mediate muscle contraction. Hyoscine Butylbromide is used for relieving abdominal pain associated with spasmodic conditions, serving as a peripheral spasmolytic. Consequently, the medication eases the physical discomfort caused by muscle contractions, a typical use scenario being the acute pain of renal colic.

Composition, Forms, and General Therapeutic Purpose

The active component, Hyoscine Butylbromide, is a semi-synthetic derivative of the naturally occurring tropane alkaloid scopolamine, chemically modified to ensure specialized action. This modification results in a unique quaternary ammonium compound structure, a feature that concentrates the drug's effect on the smooth muscle of the abdominal and pelvic systems, differentiating its therapeutic profile by minimizing central nervous system effects. Myspa is typically available for use as solid tablets for convenient oral administration and as a sterile solution for injection in ampoules for parenteral use. Its overarching therapeutic purpose is the immediate relaxation of these spastic muscles, providing symptomatic relief from cramping pain in the gastrointestinal, biliary, and genitourinary tracts. This targeted action is the key benefit, providing relief focused exactly where the spasm originates.

Regulatory References

  1. Official Hyoscine Butylbromide Monograph

What side effects are possible with Myspa?

Possible Side Effects and Safety Information

The following information details the officially documented adverse reactions and safety characteristics of Myspa, derived strictly from government regulatory product labeling.

Officially Documented Adverse Reactions

The official safety profile classifies adverse reactions based on the body systems affected and their reported frequency:

Frequency Classification System-Organ Class (SOC) Key Adverse Reactions
Common (1/100 to 1/10) Cardiac, Eye, Nervous, Gastrointestinal Tachycardia (fast heart rate), Accommodation disorders (blurred vision), Dizziness, Dry mouth, Constipation (oral forms)
Uncommon (1/1,000 to 1/100) Skin and Subcutaneous Tissue Skin reactions (e.g., urticaria, rash), Dyshidrosis (reduced sweating)
Rare (1/10,000 to 1/1,000) Renal and Urinary Urinary retention
Not Known (Frequency cannot be estimated) Immune System, Vascular, Eye, Nervous System Anaphylactic shock (including fatal outcome), Anaphylactic reactions, Hypotension (decreased blood pressure), Mydriasis, Increased intraocular pressure, Confusion, Coma, Hallucinations (rarely, following parenteral use)

Serious Adverse Reactions and Constraints

Serious Adverse Reactions: The regulatory documents highlight severe hypersensitivity reactions, including anaphylactic shock and anaphylaxis, as well as the risk of severe hypotension (decreased blood pressure), particularly following parenteral administration. Central nervous system effects such as confusion or hallucinations have been reported very rarely following injection.

Safety-Related Restrictions:

  • Patients should seek urgent ophthalmological advice if a painful, red eye with loss of vision occurs, due to the risk of undiagnosed narrow-angle glaucoma.
  • Caution is advised in patients with cardiac conditions (e.g., cardiac failure, coronary heart disease) due to the risk of tachycardia and hypotension; monitoring is advised for these patients.
  • The medication is not recommended for use during pregnancy or breastfeeding due to limited or insufficient data on its effects in these populations.

This structured regulatory safety information rigorously classifies potential risks and explicitly documents limitations, providing the official framework for understanding the medicine's safety profile.

Overdose and Emergency Response

Overdose and when to seek help

The information below summarizes the officially documented manifestations and required emergency actions for Hyoscine Butylbromide overdose, based strictly on government regulatory sources.

Documented Clinical Manifestations

Overdose presents primarily with pronounced anticholinergic symptoms, which are officially documented as dry mouth, tachycardia (fast heart rate), urinary retention, reddening of the skin, and accommodation disorders (transient visual disturbances). In cases of severe or toxic exposure, the clinical presentation can escalate to include CNS effects such as confusion, excitement, hallucinations, delirium, and potentially central nervous system depression.

Severe Outcomes and Emergency Action

Regulatory documentation warns that severe intoxication may lead to life-threatening outcomes, including respiratory paralysis, circulatory failure, and Cheynes-Stokes respiration. If an overdose is suspected, the official guidance mandates that an individual seek immediate medical attention and go to a hospital straight away. Urgent ophthalmological advice is specifically required if a patient develops a painful, red eye with loss of vision.

Management and Monitoring

Treatment for overdose is officially defined as symptomatic and supportive. Regulatory documents state that the symptoms respond to parasympathomimetics. Specific measures documented include gastric lavage with activated charcoal and the potential need for catheterisation to manage urinary retention. Special considerations are noted for children and elderly patients, who may show an increased response, with children being at risk for hyperpyrexia.

Therapeutic Uses of Myspa

What Myspa treats: Main Uses and Benefits

Myspa is used in situations involving certain distressing symptoms and is applied across domains where additional symptomatic support is needed. This medication is commonly used to help with symptomatic support for symptoms related to physical discomfort.

This class of treatment is relevant in contexts marked by increased discomfort or tension. It assists in addressing symptom clusters that may become intense or disruptive, particularly those where symptoms related to physical discomfort and inflammatory or irritative states occur together.

It is commonly used when short-term symptomatic assistance is needed. As part of managing symptoms, it supports patients during episodes of heightened discomfort. This medication is generally relevant during acute or disruptive episodes where symptoms interfere with daily functioning. By easing the overall symptom load, it contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Relief for Musculoskeletal Discomfort Myspa is commonly used to help manage acute episodes of pain and stiffness, supporting patients during temporary physiological imbalance.

Regulatory References

  1. ANALGESIC AND MUSCLE RELAXANT Product Monograph

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Myspa (Hyoscine Butylbromide)

The official regulatory profile strictly defines who is eligible for this medicine, primarily focusing on pre-existing medical conditions and life-stage factors.

Myspa is contraindicated and must not be used by individuals with conditions such as myasthenia gravis, megacolon, paralytic or obstructive ileus, and mechanical stenosis in the gastrointestinal tract. Parenteral (injection) administration is also strictly prohibited in patients with untreated narrow-angle glaucoma, prostatic hypertrophy leading to urinary retention, tachycardia, angina, or cardiac failure.

The medicine is generally allowed for use in adults. However, for specific life-stage groups, use is not recommended in pregnant and breastfeeding women due to insufficient data on human safety. The oral tablet is also not recommended for children under six years of age.

Several groups require caution or special consideration. Patients with existing cardiac conditions need close monitoring, and the intramuscular injection route is contraindicated for patients receiving anticoagulant drugs. Furthermore, the tablet formulation is contraindicated for individuals with rare hereditary problems of sugar intolerance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope and Classifications

The official regulatory profile for Myspa (Hyoscine Butylbromide) is primarily defined by pharmacodynamic interactions and specific administrative restrictions. Co-administration with other medicinal products possessing anticholinergic properties may lead to an intensified anticholinergic effect, classified as a clinically significant interaction. This category includes drugs such as tricyclic and tetracyclic antidepressants, certain antihistamines, antipsychotics, Quinidine, Amantadine, and Disopyramide. In addition, the heart-rate increasing effects (chronotropic action) of Beta-Adrenergic Agents may be enhanced.

Official Interaction Statements and Restrictions

  • A documented antagonistic pharmacodynamic effect occurs with Dopamine Antagonists, including Metoclopramide or Domperidone, resulting in the diminution of effects on gastrointestinal motility for both substances.
  • Due to the risk of reduced gastrointestinal motility, Myspa may affect the absorption of other oral medications, suggesting a need for dose separation from other oral agents.
  • A specific route-related prohibition is formally stated: Intramuscular injection is officially contraindicated in patients receiving anticoagulant drugs due to the risk of intramuscular haematoma.
  • Consumption of alcohol is prohibited with the injection formulation, as documented in regulatory information.

Connection to the overall interaction profile

The medicine’s interaction structure centers on enhancing or opposing the actions of other agents that affect the parasympathetic nervous system. Regulatory information formally identifies these interaction outcomes, necessary use-with-caution constraints, and the formalized prohibition dictated by the administration route. The profile is limited to documented interaction data and constraints.

Mechanism of Action

Myspa is a combination medication that operates through three distinct mechanistic domains, which collectively modulate key physiological pathways.


Modulating Prostaglandin Synthesis Pathways

This domain involves enzyme-mediated signaling where a drug component inhibits cyclooxygenase (COX-1 and COX-2) enzymes. By blocking these key enzymes, the synthesis of specific prostaglandin mediators—signaling molecules whose production is amplified during specific physiological responses—is suppressed. This modification of an early molecular step modifies the concentration of specific signaling mediators within the inflammatory pathway.


Influencing Central Signaling Pathways

The second domain supports the regulation of processes driven by distinct central signaling patterns, particularly within the central nervous system (CNS). The agent in this domain is believed to inhibit prostaglandin synthesis primarily in the CNS and may also affect hypothalamic thermoregulation centers. This mechanism leads to the central modification of neuronal signaling associated with the targeted pathway.


Regulating Peripheral Smooth Muscle Tone

The third mechanistic domain involves receptor-mediated signaling where a drug component acts as an anticholinergic agent by inhibiting the effect of acetylcholine at muscarinic receptors in smooth muscle tissues. This mechanism modulates the activity of visceral smooth muscle by reducing the excitability and contractile force of the tissue, and modulating the downstream effects of cholinergic activation in these systems.

Dosage and Administration Information

The following is a summary of the administration instructions for Naltrexone/Bupropion prolonged-release tablets (such as Myspa or Contrave).

Dosing Schedule and Administration

The medicine is administered orally and must be swallowed whole with water. Tablets should not be cut, chewed, or crushed to maintain the integrity of the prolonged-release formulation. It is generally recommended to take the tablets with food, but they should not be taken with high-fat meals.

Initial treatment requires a four-week dose escalation to minimize adverse effects:

Week Morning Dose Evening Dose Total Daily Dose
1 1 tablet None 1 tablet
2 1 tablet 1 tablet 2 tablets
3 2 tablets 1 tablet 3 tablets
4+ 2 tablets 2 tablets 4 tablets (Maximum)

The maximum recommended daily dose is four tablets (32 mg naltrexone / 360 mg bupropion). If a dose is missed, the instruction is not to take an additional dose but to resume the prescribed schedule at the usual time.

Dose Adjustments and Duration

Specific maximum dose adjustments are required for certain patient populations. For patients with moderate-to-severe kidney impairment or mild liver impairment, the maximum daily dose is reduced to two tablets (one in the morning and one in the evening).

Use in the pediatric population (under 18 years of age) is not established. Caution is advised when prescribing for patients over 65 years of age. The treatment protocol indicates that therapy is discontinued after 16 weeks if the patient has not achieved a minimum of 5% loss of baseline body weight, as continued benefit is unlikely.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Myspa

Evidence for Acute Cramping Pain in the Digestive Tract

Research for this specific context is primarily relevant in trials assessing short-term or episodic symptom patterns. The initial evidence base includes Randomized Controlled Trials (RCTs) where the medicine was studied for outcomes related to physical discomfort in patients experiencing acute, disruptive episodes of cramping pain. The research examined how symptoms evolved in the observed populations during the immediate hours following treatment. Studies reported measurements of changes in symptom intensity, often utilizing patient-reported outcomes describing perceived discomfort. Some trials described patterns where the time required for patients to report a change in their reported pain was measured during the study period. Follow-up durations were often limited to the acute period of symptom activity, meaning that there is limited information for long-term outcomes regarding how repeated use over many months might contributes to understanding symptom patterns.

Research on Symptoms Related to Irritable Bowel Syndrome (IBS)

The medicine was evaluated in studies for its use in conditions characterized by fluctuating or episodic manifestations, particularly the abdominal discomfort associated with Irritable Bowel Syndrome. Research explored outcomes reflecting daily functioning or activity level, alongside patient-reported outcomes describing perceived discomfort. Evidence contributes to understanding symptom patterns, with some trials reporting measurements of higher patient global assessments compared to placebo. Long-term effects are not fully established regarding the sustained management of symptom activity in IBS. Comparative evidence against a variety of newer agents remains an area of research.

Evidence Gaps and Areas of Uncertainty

A synthesized review of the evidence shows that research provides insight into short-term changes, but several limitations exist. Findings were mixed or inconsistent in some comparative trials where the medicine was evaluated against other common analgesic agents. Furthermore, the available data for certain populations remain insufficient, and sample sizes were often small in some older studies. The certainty remains low regarding the full range of potential outcomes from long-term, repeated use. Research highlights what is known — and what is still uncertain about the medicine’s use across the broad landscape of spasmodic conditions.

Key Studies & References

  1. A Comprehensive Review of the Effects of Hyoscine Butylbromide in Childhood
  2. Public Assessment Report Pharmacy to General Sales List Reclassification Buscopan IBS Relief Hyoscine Butylbromide 10mg PL 53886

Frequently Asked Questions (FAQ)

Common questions about Myspa (FAQ)

Q: How quickly does Myspa start working after you take it?

A: Myspa is a muscle relaxant that acts to ease spasms. Official product information indicates that the medicine is quickly absorbed by the tissue after oral administration, concentrating in the gastrointestinal tract, liver, and kidneys to begin its effect on spasms.

Q: How long does the effect of Myspa usually last?

A: Studies on the medicine’s pharmacology show that while the half-life of the blood levels is very short, the medication has a high affinity for smooth muscle tissue. This high tissue concentration is thought to sustain its effect at the site of action, though individual duration may vary.

Q: Does Myspa cause stomach upset or nausea?

A: Official safety data lists common gastrointestinal side effects as dry mouth and constipation. Nausea is not a common side effect but has been reported in very rare cases in post-marketing experience.

Q: What should I do if the side effects of Myspa are bothering me?

A: The official safety profile advises patients to seek urgent medical attention if signs of a severe allergic reaction (like difficulty breathing or feeling faint) or a painful, red eye with loss of vision occur. For other side effects, regulatory guidance recommends consulting with a doctor or pharmacist.

Q: What are the signs of a severe allergic reaction to Myspa?

A: Official documents state that signs of a severe allergic reaction (anaphylactic shock) may include difficulty breathing, feeling faint or dizzy (signs of shock), and severe skin reactions such as nettle rash, itching, or rash.

Q: How does Myspa work to treat [Targeted symptom/condition]?

A: Myspa acts as an anticholinergic agent by specifically targeting muscarinic receptors on the smooth muscle cells of the gastrointestinal tract. This targeted action produces a spasmolytic, or muscle-relaxing, effect, which is intended to provide symptomatic relief for acute cramping pain.

Q: Does Myspa affect my ability to drive or operate machinery?

A: Since some people may experience temporary sight problems or dizziness when taking this medicine, official guidance advises caution. If your vision is affected, official guidance advises waiting until vision returns to normal before attempting to drive or use any tools or machines.

Q: How long does it take for Myspa to clear out of your system?

A: Clearance of the medicine involves both the kidneys (renal) and elimination through the faeces. Official pharmacokinetic studies indicate that more than 90% of an oral dose is eliminated unchanged in the faeces.

Q: Can you take Myspa every day?

A: Official regulatory information states that the medicine is not intended for continuous daily or extended use. This is because the cause of the underlying abdominal pain should be subject to prior medical investigation.

Q: Is it normal to feel dizzy or drowsy after taking Myspa?

A: Dizziness is a commonly reported side effect. However, due to the medicine’s chemical structure, it is not expected to readily enter the central nervous system, which minimizes the occurrence of centrally-mediated effects like drowsiness or sleepiness.

Q: Does Myspa have any known side effects related to sleep?

A: The drug is not expected to readily cross the blood-brain barrier, which helps minimize centrally-mediated effects such as somnolence. Official safety profiles do not typically list common sleep disturbances.

Q: Is Myspa habit-forming or addictive?

A: The medication is not centrally active and is considered to have a low abuse potential. However, regulatory reports have mentioned rare cases of misuse, particularly when the tablets are illegally altered.

Q: Are there different strengths or formulations of Myspa?

A: Yes, official documentation indicates that the medicine is available in different forms. It is typically supplied as tablets for oral use and as a solution for injection in different strengths.

Q: Does Myspa cause changes in mood or behavior?

A: The drug is not expected to enter the central nervous system. However, in very rare post-marketing cases, psychiatric disorders such as confusion or hallucinations have been reported, particularly following injection.

Q: Can people with liver problems use Myspa?

A: Regulatory information indicates that patients with hepatic (liver) or renal (kidney) impairment may require a dose adjustment. This is due to the potential for altered drug metabolism or excretion in these populations.

Q: What if I take other oral medications close to Myspa?

A: Since this medicine can temporarily reduce how quickly food and medicine move through the gut, it may affect the absorption of other oral drugs. Official guidance indicates that anticholinergics like Myspa may be administered at least one hour before other oral medications to manage absorption risks.

Q: What is the maximum number of days you can take Myspa in a row?

A: Myspa is intended for the symptomatic relief of acute spasms. Regulatory information states that it should not be taken for extended periods without a doctor investigating the cause of the abdominal pain.

Q: Are there generic versions of Myspa available?

A: Yes, regulatory and health authorities confirm that medicines containing the same active ingredient, Hyoscine Butylbromide, are available from different manufacturers and under various brand names.

How should Myspa be stored and disposed of?

Myspa (Hyoscine Butylbromide) must be stored and disposed of strictly according to official regulatory instructions.

Storage Conditions

The medicine must be stored below 30 C (or 25 C for the injection form) and requires protection from light and moisture. Storage must always be in the original container, which should be kept in a cool, dry place. Storage locations that are prone to high heat or dampness, such as a bathroom or a car, are prohibited, as these conditions can compromise product integrity.

Handling and Child Safety

All forms of Myspa must be securely stored out of the reach of children and pets. The solution for injection is strictly for single use only, and any unused portion must be discarded immediately after use. The product must not be used past the printed expiry date.

Disposal

Unused or expired Myspa must not be disposed of in household trash or down the sink/toilet as this can pollute waterways. Disposal must comply with local regulations. Users are instructed to consult a pharmacist about local medicine take-back programs or safe disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Myspa found in:

A-Z Index: